Menu Search
Equities

Syros Pharmaceuticals Inc

0S90:FRA

Syros Pharmaceuticals Inc

Actions
  • Price (EUR)2.32
  • Today's Change0.10 / 4.50%
  • Shares traded2.76k
  • 1 Year change-14.07%
  • Beta--
Data delayed at least 15 minutes, as of Nov 08 2024 07:06 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Syros Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing new standards of care for the frontline treatment of patients with hematologic malignancies. The Company is advancing Tamibarotene, a selective retinoic acid receptor alpha (RARα), agonist for which the Company is conducting SELECT-MDS-1, a Phase III clinical trial evaluating tamibarotene in combination with azacitidine in a genomically defined subset of patients with higher-risk myelodysplastic syndrome (HR-MDS), and for which it is conducting SELECT-AML-1, a randomized Phase II clinical trial evaluating tamibarotene in combination with venetoclax and azacitidine in a genomically defined subset of newly diagnosed patients with acute myeloid leukemia (AML). Its other assets include SY-2101 and SY-5609. The Company is seeking out-licensing opportunities for the further development of SY-5609, its highly selective and potent inhibitor of cyclin dependent kinase 7 (CDK7).

  • Revenue in USD (TTM)386.00k
  • Net income in USD-97.82m
  • Incorporated2011
  • Employees68.00
  • Location
    Syros Pharmaceuticals Inc35 Cambridge Park DriveCAMBRIDGE 02140United StatesUSA
  • Phone+1 (617) 744-1340
  • Fax+1 (617) 744-1377
  • Websitehttps://syros.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.